Download PDF

1. Company Snapshot

1.a. Company Description

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide.It operates in two segments, Medical and Isotope Products.The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma.


This segment also provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as eye applicators and prostate implants.The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, material analysis, quality assurance, and environmental monitoring.This segment also offers calibration sources for medical imaging systems, and homeland security and radiometric level measurement products.


The company was founded in 1992 and is headquartered in Berlin, Germany.

Show Full description

1.b. Last Insights on EUZ

Eckert & Ziegler's recent performance was impacted by a weak quarter, with the share price falling 22%. Although the company's Q2 2025 earnings showed a slight improvement in EPS (€0.19 vs €0.17 in 2Q 2024) and revenue growth (3.7% from 2Q 2024 to €80.6m), investors' expectations seem to have been unmet. The radiopharmaceutical CDMO market, where Eckert & Ziegler operates, is expected to grow at a 9.3% CAGR, but intense competition and high research and development costs might weigh on the company's profitability.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Eckert & Ziegler SE's (ETR:EUZ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Dec -01

Source:

Card image cap

Undiscovered Gems in Europe to Explore This November 2025

Nov -14

Source:

Card image cap

[Latest] Global Radiopharmaceutical CDMO Market Size/Share Worth USD 7.2 Billion by 2034 at a 9.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Oct -23

Source:

Card image cap

Exploring Three Undiscovered European Gems With Potential

Oct -03

Source:

Card image cap

Eckert & Ziegler (ETR:EUZ) jumps 5.3% this week, though earnings growth is still tracking behind three-year shareholder returns

Sep -14

Source:

Card image cap

Societe Generale: shares & voting rights as of 31 August 2025

Sep -09

Source:

Card image cap

Vaisala Corporation: Share Repurchase 9.9.2025

Sep -09

Source:

Card image cap

Assessing Acciona (BME:ANA)'s Valuation After Recent Subtle Moves

Sep -09

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.93%)

6. Segments

Isotope Products

Expected Growth: 7%

Eckert & Ziegler's Isotope Products segment growth is driven by increasing demand for nuclear medicine and radioisotope applications, expansion into emerging markets, strategic partnerships, and investments in research and development to enhance product offerings and improve manufacturing efficiency.

Medical

Expected Growth: 9%

Eckert & Ziegler's 9% growth in Medical segment is driven by increasing demand for radiopharmaceuticals, expansion in emerging markets, and strategic acquisitions. Growing need for cancer treatment and diagnostic imaging also contribute to growth. Additionally, the company's focus on research and development of new products and technologies enhances its market position.

7. Detailed Products

Radiopharmaceuticals

Eckert & Ziegler develops and manufactures radiopharmaceuticals for diagnostic and therapeutic applications, including cancer treatment and imaging.

Radioisotope Generators

Eckert & Ziegler designs and manufactures radioisotope generators for the production of short-lived radioisotopes, used in medical research and diagnostics.

Radiation Detection and Measurement

Eckert & Ziegler offers a range of radiation detection and measurement instruments for industrial, medical, and research applications.

Medical Imaging

Eckert & Ziegler provides medical imaging solutions, including SPECT and PET cameras, for diagnostic imaging in hospitals and research institutions.

Cancer Treatment

Eckert & Ziegler develops and manufactures cancer treatment solutions, including brachytherapy and external beam therapy.

Radiation Therapy

Eckert & Ziegler provides radiation therapy solutions, including external beam therapy and brachytherapy, for cancer treatment.

8. Eckert & Ziegler Strahlen- und Medizintechnik AG's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Eckert & Ziegler Strahlen- und Medizintechnik AG is moderate, as there are alternative products and services available in the market, but they are not highly substitutable.

Bargaining Power Of Customers

The bargaining power of customers for Eckert & Ziegler Strahlen- und Medizintechnik AG is low, as the company operates in a niche market with limited customer base, and customers have limited bargaining power.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Eckert & Ziegler Strahlen- und Medizintechnik AG is moderate, as the company relies on a few key suppliers for its raw materials, but has some bargaining power due to its size and reputation.

Threat Of New Entrants

The threat of new entrants for Eckert & Ziegler Strahlen- und Medizintechnik AG is low, as the company operates in a highly regulated industry with high barriers to entry, and new entrants would face significant challenges in entering the market.

Intensity Of Rivalry

The intensity of rivalry for Eckert & Ziegler Strahlen- und Medizintechnik AG is high, as the company operates in a highly competitive market with several established players, and the company needs to continuously innovate and differentiate itself to maintain its market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 20.22%
Debt Cost 9.41%
Equity Weight 79.78%
Equity Cost 9.41%
WACC 9.41%
Leverage 25.34%

11. Quality Control: Eckert & Ziegler Strahlen- und Medizintechnik AG passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
InMode

A-Score: 4.9/10

Value: 6.6

Growth: 7.0

Quality: 9.4

Yield: 0.0

Momentum: 3.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
ChemoMetec

A-Score: 4.8/10

Value: 0.0

Growth: 7.8

Quality: 9.4

Yield: 0.6

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Eckert & Ziegler

A-Score: 4.7/10

Value: 2.0

Growth: 7.1

Quality: 7.5

Yield: 1.2

Momentum: 7.5

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
CellaVision

A-Score: 3.5/10

Value: 1.3

Growth: 6.7

Quality: 8.0

Yield: 1.9

Momentum: 0.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Xvivo Perfusion

A-Score: 3.3/10

Value: 0.8

Growth: 9.8

Quality: 7.5

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Guerbet

A-Score: 2.7/10

Value: 7.8

Growth: 2.6

Quality: 2.0

Yield: 2.5

Momentum: 0.0

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

15.47$

Current Price

15.47$

Potential

-0.00%

Expected Cash-Flows